Linked Life Data

20371484

Source:http://linkedlifedata.com/resource/pubmed/id/20371484

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
19
pubmed:dateCreated
2010-4-7
pubmed:abstractText
The U.S. National Institutes of Health Roadmap and the U.S. Food and Drug Administration's Critical Path Initiative have endorsed the establishment of large academic clinical research networks as part of the solution to the growing divide between increased R&D spending and the lagging number of new drugs making it to market. Clearly, the role of these networks as translational science incubators that complement industry-sponsored programs is laudable and much-needed. However, the path to success for such organizations is less clear. Here, drawing on the experiences of the Immune Tolerance Network, a multidisciplinary clinical research network founded in 1999, we discuss some of the barriers inherent in developing such consortia and offer firsthand insight into the planning, resources, and organizational infrastructure required for a successful research program.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1946-6242
pubmed:author
pubmed:issnType
Electronic
pubmed:day
17
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
19cm7
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Ten years of the Immune Tolerance Network: an integrated clinical research organization.
pubmed:affiliation
Immune Tolerance Network, University of California, San Francisco, San Francisco, CA 94107, USA.
pubmed:publicationType
Journal Article